Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6959126 | 0.81 | HDAC1 (0.65) | HDAC1HDAC8SMN1; SMN2KDM4EHPGD | |
| SCHEMBL10971761 | 0.80 | HDAC1 (0.63) | HDAC1HDAC8SMN1; SMN2KDM4EHPGD | |
| SCHEMBL5641458 | 0.80 | HDAC1 (0.63) | HDAC1HDAC8SMN1; SMN2KDM4EHPGD | |
| SCHEMBL30161792 | 0.80 | SMN1; SMN2 (0.69) | HDAC1HDAC8SMN1; SMN2KDM4EHPGD | |
| SCHEMBL13443094 | 0.80 | PTPN1 (0.69) | HDAC1HDAC8SMN1; SMN2KDM4EHPGD | |
| SCHEMBL4931148 | 0.80 | SMN1; SMN2 (0.69) | HDAC1HDAC8SMN1; SMN2KDM4EHPGD | |
| SCHEMBL8780100 | 0.80 | HDAC1 (0.68) | HDAC1HDAC8SMN1; SMN2KDM4EHPGD | |
| SCHEMBL2035615 | 0.79 | TDP1 (0.67) | HDAC1HDAC8SMN1; SMN2KDM4EHPGD | |
| SCHEMBL8533379 | 0.79 | SMN1; SMN2 (0.61) | HDAC1HDAC8SMN1; SMN2KDM4EHPGD | |
| SCHEMBL8598241 | 0.79 | HDAC1 (0.66) | HDAC1HDAC8SMN1; SMN2KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270855-A1 | Methods of preparing retroviral proteases inhibitor intermediates | G.D. SEARLE & CO. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7060851-B2 | Method of preparing retroviral protease inhibitor intermediates | G.D. SEARLE & CO. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20050131075-A1 | Method of preparing retroviral protease inhibitor intermediates | G.D. SEARLE & CO. (US) | 2005-06-16 | — | — | US | disclosed |
| CN-1623977-A | Method of preparing retroviral protease inhibitor intermediates | SEARLE & CO (US) | 2005-06-08 | — | — | CN | disclosed |
| US-6849760-B2 | Method of preparing retroviral protease inhibitor intermediates | G. D. SEARLE & CO. (US) | 2005-02-01 | — | — | US | disclosed |
| EP-0970066-B1 | Preparation of aminoepoxides from aminoaldehydes and an in situ formed halomethyl organometallic reagent | SEARLE & CO (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030171612-A1 | Method of preparing retroviral protease inhibitor intermediates | G.D. SEARLE & CO. | 2003-09-11 | — | — | US | disclosed |
| US-6515162-B2 | Precipitating or crystallizing a salt from solution; suitable as intermediates for large scale production of enzyme inhibitors, e.g. hydroxyethylamine, hydroxyethylurea and hydroxyethylsulfonamide | G.D. SEARLE & CO. | 2003-02-04 | — | — | US | disclosed |
| EP-0855388-B1 | Method for making intermediates useful in synthesis of retroviral protease inhibitors | SEARLE & CO (US) | 2002-03-06 | — | — | EP | disclosed |
| US-20010047111-A1 | Method of preparing retroviral protease inhibitor intermediates | NG JOHN S (US) | 2001-11-29 | — | — | US | disclosed |
| US-5872299-A | Method of preparing intermediates for retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1999-02-16 | — | — | US | disclosed |
| US-5831117-A | ACID SALTS | G. D. SEARLE & CO. (US) | 1998-11-03 | — | — | US | disclosed |
| EP-0855388-A2 | Method for making intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1998-07-29 | — | — | EP | disclosed |
| WO-1998029401-A1 | AMINOEPOXIDES FROM AMINOALDEHYDES AND IN-SITU FORMED HALOMETHYL ORGANOMETALLIC REAGENT | G.D. SEARLE & CO. (US) | 1998-07-09 | — | — | WO | disclosed |
| CN-1177955-A | Process for preparing retroviral protease inhibitor intermediates | SEARLE & CO (US) | 1998-04-01 | — | — | CN | disclosed |
| EP-0804410-A1 | METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5648511-A | Method for making intermediates useful in the synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1997-07-15 | — | — | US | disclosed |
| EP-0730570-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-11 | — | — | EP | disclosed |
| WO-1996022275-A1 | METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES | G.D. SEARLE & CO. (US) | 1996-07-25 | — | — | WO | disclosed |
| WO-1995014653-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270855-A1 | Methods of preparing retroviral proteases inhibitor intermediates | ACE, REN, MME | HDAC1 1795/4885HDAC8 2703/4885SMN1; SMN2 2989/4885 |
| US-20030171612-A1 | Method of preparing retroviral protease inhibitor intermediates | ACE, REN, MME | HDAC1 1592/4885HDAC8 2440/4885SMN1; SMN2 2891/4885 |
| US-20010047111-A1 | Method of preparing retroviral protease inhibitor intermediates | ACE, REN, MME | HDAC1 1592/4885HDAC8 2440/4885SMN1; SMN2 2891/4885 |
| US-20050131075-A1 | Method of preparing retroviral protease inhibitor intermediates | ACE, REN, MME | HDAC1 1734/4885HDAC8 2431/4885SMN1; SMN2 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.